Nevolat vs Mounjaro: Comparing Two Weight-Loss Options

Step 1, Understand what each product actually is

Mounjaro is the brand name for tirzepatide, a dual GIP and GLP-1 receptor agonist made by Eli Lilly. It is the only medicine of its kind licensed in the UK for weight management and type 2 diabetes. It works by activating two gut-hormone receptors that regulate appetite and blood-sugar levels, slowing gastric emptying and increasing the feeling of fullness. According to the NHS medicines page for tirzepatide, it is given as a once-weekly subcutaneous injection using a pre-filled KwikPen. Because it is a Prescription-Only Medicine, a prescriber must assess your health before you can legally obtain it.

Nevolat is a food supplement sold without a prescription. It typically contains a blend of plant extracts and vitamins positioned to support weight management. Supplements of this kind are not regulated by the MHRA as medicines, are not assessed for efficacy against clinical endpoints, and are not subject to the same evidence requirements as licensed medicines. If you want to understand how Mounjaro sits alongside other prescription alternatives before drawing any conclusions, our comparison of Reta and Mounjaro sets out how two very different regulated options stack up. The comparison between nevolat and Mounjaro is therefore not really a like-for-like one: they are regulated entirely differently and the evidence base behind them is in a different order of magnitude.

That distinction matters because it shapes every other part of this comparison, price, results, safety monitoring and access.

Step 2, Look at what the evidence actually shows

The evidence for Mounjaro in weight management is substantial. The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity and followed them for 72 weeks. Participants on the 15 mg dose saw an average body-weight reduction of around 20–21%. In the more recent SURMOUNT-5 trial (published in the NEJM, 2025), tirzepatide produced greater average weight loss than semaglutide 2.4 mg in a head-to-head comparison over 72 weeks. NICE reviewed this evidence and recommended tirzepatide for eligible adults under technology appraisal TA1026.

For Nevolat, no peer-reviewed randomised controlled trial data is available in the public domain at the level required for a NICE appraisal. Supplement manufacturers are permitted to use general health claims approved by the Food Standards Agency, but these are not equivalent to clinical evidence of meaningful weight reduction. If you have seen comparison figures for nevolat online, treat them with caution, they will not have been assessed by the MHRA or NICE.

The table below sets out the key factual differences at a glance.

Step 3, Consider eligibility and access for Mounjaro

Because Mounjaro is a prescription medicine, access follows a clinical pathway. The licensed criteria cover adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes or obstructive sleep apnoea. Lower BMI thresholds can apply for certain ethnic backgrounds under UK clinical guidance. A prescriber also considers your full medical history, current medicines and any contraindications before approving treatment, BMI alone does not decide it.

Nevolat, as a supplement, has no access restrictions beyond purchase. That is sometimes presented as a benefit, but the absence of a clinical gate also means there is no professional reviewing whether it is appropriate for you, whether it interacts with your medicines, or whether there is a more effective option. For many people exploring nevolat, the underlying goal is meaningful, sustained weight loss, and that is precisely what the prescription route is designed to address.

If you are weighing up whether Mounjaro is the right path, our Mounjaro overview covers eligibility, how the dose titration works and what to expect from treatment. You can also explore how tirzepatide compares with other prescription options, including a detailed look at how GLP-1 medicines differ from Mounjaro and what that means in practice or how it stacks up against orlistat.

Step 4, Weigh up cost in the right context

Nevolat is available at a lower upfront cost than Mounjaro. That is a factual point, and it is worth being honest about. However, cost comparisons between a supplement and a prescription medicine are measuring different things. Mounjaro's price through a private pharmacy includes a clinical consultation, a prescriber's assessment, a licensed medicine dispensed through a regulated supply chain, and ongoing clinical oversight. The supplement price includes none of that infrastructure.

Since Eli Lilly raised Mounjaro's UK list price in September 2025, typical private prices range from roughly £149 to around £375 per month depending on dose and provider (as widely reported). Reviewing those figures carefully (including what each provider's price actually includes) is worth doing before you commit. Our Mounjaro prices page explains what drives the cost and what a legitimate price should cover. At nume, one price covers consultation, prescription, treatment and aftercare. There are no add-ons, no repeat-billing surprises.

If your search landed here around payday or just before a bank holiday, it is worth knowing that orders placed before 12pm on a working day are dispatched that same day once approved, so timing your order thoughtfully means you are not waiting over a long weekend. Side effects such as constipation are common when starting tirzepatide, and our guide on choosing the right laxative while taking Mounjaro can help you manage them comfortably. For a broader look at the prescription weight-loss landscape, the weight-loss treatments overview is a useful starting point.